At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 478 enrolled
Drug / intervention
Lurasidone +3 moredrug
Likely dose
Lurasidone 40 mg tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Placebo-and Active Comparator Controlled, Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia.
In Brief
A Phase 3 clinical trial evaluating Lurasidone, Olanzapine, and 2 other interventions for Schizophrenia. Completed, enrolled 478 participants across 52 sites in 5 countries.
Detailed Summary
Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesColombia, India, Lithuania, Philippines, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionDec 2009
Study CompletionJan 2010
TodayJul 2026
First PostedFeb 14, 2008
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.4 years ago
Interventions
Lurasidonedrug
120mg/day
Olanzapinedrug
15mg/day
Placebo comparatordrug
Placebor Comparator
Lurasidone 40 mg tabletsdrug
Lurasidone 40 mg tablets